Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

NCT ID: NCT05092451

This clinical trial is exploring a new treatment approach for patients with certain blood cancers, including B-Cell Lymphoma, Myelodysplastic Syndromes (MDS), and Acute Myeloid Leukemia (AML). The ...

Recruiting

Phase: PHASE1 Type: interventional Locations: Houston, Texas, United States

Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma

NCT ID: NCT06182774

This clinical trial is studying the effectiveness of two different ways to use a medication called daratumumab in older adults who have just been diagnosed with multiple myeloma and are not able to...

Recruiting

Phase: PHASE3 Type: interventional Locations: Saskatoon, Saskatchewan, Canada, Saint John, New Brunswick, Canada +26 more

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

NCT ID: NCT06876142

This clinical trial is looking at a new treatment for adults with relapsed or refractory multiple myeloma (RRMM), a type of blood cancer that often comes back after treatment or doesn’t respond to ...

Recruiting

Phase: PHASE1 Type: interventional Locations: Bethesda, Maryland, United States

Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse

NCT ID: NCT06910124

This clinical trial is studying a new treatment for patients with multiple myeloma, a type of blood cancer. The researchers want to see if combining a medication called linvoseltamab with lenalidom...

Recruiting

Phase: PHASE2 Type: interventional Locations: Miami, Florida, United States

A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

NCT ID: NCT07105059

This clinical trial is studying a new treatment approach for people with multiple myeloma, a type of blood cancer, who have already tried other treatments without success. The study is testing a co...

Recruiting

Phase: PHASE1 Type: interventional Locations: New York, New York, United States, Basking Ridge, New Jersey, United States +5 more

A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

NCT ID: NCT06953960

This clinical trial is studying a new medication called ABBV-453 for adults with multiple myeloma (MM), a type of cancer affecting the bone marrow. The trial aims to find out how safe ABBV-453 is a...

Recruiting

Phase: PHASE1 Type: interventional Locations: Tacoma, Washington, United States, Ramat Gan, Tel Aviv, Israel +9 more

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

NCT ID: NCT06817889

This clinical trial is studying a medication called remdesivir to see if it can effectively treat upper respiratory tract infections caused by the respiratory syncytial virus (RSV) in individuals w...

Not yet recruiting

Phase: PHASE2 Type: interventional Locations: Duarte, California, United States, Seattle, Washington, United States +1 more

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

NCT ID: NCT05583617

This clinical trial, titled "A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma," is testing various treatment combinations for people diagnosed...

Recruiting

Phase: PHASE1 Type: interventional Locations: Valencia, , Spain, Badalona, , Spain +27 more

Elranatamab in R/R Multiple Myeloma

NCT ID: NCT06138275

This clinical trial is studying a new treatment called elranatamab for patients with relapsed or refractory multiple myeloma, which means their cancer has returned or hasn’t responded to previous t...

Recruiting

Phase: PHASE2 Type: interventional Locations: Boston, Massachusetts, United States, Boston, Massachusetts, United States +1 more

National Cancer Institute "Cancer Moonshot Biobank"

NCT ID: NCT04314401

The "Cancer Moonshot Biobank" is a clinical trial that aims to gather blood and tissue samples from patients diagnosed with various types of cancer, including advanced stages of breast cancer, lung...

Recruiting

Type: observational Locations: Des Moines, Iowa, United States, Scarborough, Maine, United States +181 more

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

NCT ID: NCT06348108

This clinical trial is studying a new treatment combination for patients with multiple myeloma, a type of blood cancer that can come back after treatment or does not respond to previous therapies. ...

Recruiting

Phase: PHASE1 Type: interventional Locations: San Francisco, California, United States

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

NCT ID: NCT06892522

This clinical trial is designed to evaluate a new treatment called Etentamig (ABBV-383) for adults with multiple myeloma, a type of cancer affecting the blood's plasma cells. The study aims to dete...

Recruiting

Phase: PHASE1 Type: interventional Locations: Ramat Gan, Tel Aviv, Israel, Haifa, , Israel +4 more

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

NCT ID: NCT07095452

This clinical trial is studying a new treatment option for adults who have recently been diagnosed with multiple myeloma, a type of blood cancer that affects the bones and bone marrow. The trial is...

Not yet recruiting

Phase: PHASE2 Type: interventional

A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

NCT ID: NCT06934044

This clinical trial is studying a new treatment called cevostamab for patients with a type of blood cancer known as multiple myeloma, specifically in those whose disease has come back or hasn’t res...

Recruiting

Phase: PHASE1 Type: interventional Locations: Nanchang, , China, Wenzhou City, , China +2 more

A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma

NCT ID: NCT06235229

This clinical trial is investigating a new treatment called GC012F for patients with relapsed or refractory multiple myeloma, which means their cancer has returned or hasn’t responded to previous t...

Recruiting

Phase: PHASE1 Type: interventional Locations: Shanghai, Shanghai, China, Shanghai, , China +12 more

External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease

NCT ID: NCT06572605

This clinical trial is studying a new treatment approach for patients with multiple myeloma who have a specific condition known as extramedullary disease (EMD), where cancer cells infiltrate organs...

Recruiting

Phase: PHASE1 Type: interventional Locations: Duarte, California, United States

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

NCT ID: NCT06679101

This clinical trial is investigating a new treatment approach for patients with newly diagnosed multiple myeloma, a type of blood cancer. The study compares two treatment combinations: one that inc...

Recruiting

Phase: PHASE3 Type: interventional Locations: Madrid, , Spain, Madrid, , Spain +65 more

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

NCT ID: NCT02693535

The TAPUR trial is studying how effective certain FDA-approved drugs are for patients with advanced cancers, such as lymphoma, multiple myeloma, and solid tumors, that have specific genetic changes...

Recruiting

Phase: PHASE2 Type: interventional Locations: Ann Arbor, Michigan, United States, Philadelphia, Pennsylvania, United States +188 more

18F-Fluciclovine PET/CT in Multiple Myeloma

NCT ID: NCT06103838

This clinical trial is studying a new imaging method using a substance called 18F-fluciclovine to see if it can better detect multiple myeloma (MM), a type of blood cancer, compared to the current ...

Recruiting

Phase: PHASE2 Type: interventional Locations: Bethesda, Maryland, United States

Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

NCT ID: NCT06216158

This clinical trial is looking to see if adding a drug called isatuximab to a maintenance therapy with iberdomide can help patients with newly diagnosed multiple myeloma keep their cancer under con...

Recruiting

Phase: PHASE3 Type: interventional Locations: Oldenburg, , Germany, Stuttgart, , Germany +77 more

Main Menu

Clinical Trials for Multiple Myeloma

421 Active Trials Found

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse

A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

Elranatamab in R/R Multiple Myeloma

National Cancer Institute "Cancer Moonshot Biobank"

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma

External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

18F-Fluciclovine PET/CT in Multiple Myeloma

Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

Related Conditions